There are currently 67 clinical trials in Irving, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University Hills Clinical Research, Pfizer Investigational Site, GSK Investigational Site and Next Oncology-Dallas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402
Recruiting
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Investigational Site (526), Irving, Texas
Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
02/27/2025
Locations: Optum Infusion - Irving, Irving, Texas
Conditions: Alzheimer Disease
Register for Updates
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
NCT06588296
Recruiting
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/26/2025
Locations: AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving, Irving, Texas
Conditions: Psoriatic Arthritis, Obesity
Register for Updates
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Advanced Solid Malignancies
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/19/2025
Locations: Tekton Research, Irving, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839
Recruiting
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: US Oncology Investigational Products Center (IPC), Irving, Texas
Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Register for Updates
Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977
Recruiting
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: US Oncology Investigational Product Center (IPC), Irving, Texas +1 locations
Conditions: Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Register for Updates
DIALYSIS-TIR Study
NCT06042153
Recruiting
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: DaVita UT Southwestern - Irving, Irving, Texas
Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Register for Updates
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144
Recruiting
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
02/10/2025
Locations: Research Site, Irving, Texas
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
NCT06162221
Recruiting
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first three subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
Register for Updates
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478
Recruiting
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences.
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Baylor - Christus Children's - Main Hospital, Irving, Texas
Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Register for Updates